A resolution designating the first full week in May as "Tardive Dyskinesia Awareness Week".
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill defines designates the first full week in May as Tardive Dyskinesia Awareness Week and promotes awareness of this medication side effect through encouraging early detection, intervention, and routine screening. It relies on definition changes. The main policy areas are Healthcare and Trade.
Who Benefits and How
Mental health advocacy organizations and patient support groups could gain revenue opportunities.
Who Bears the Burden and How
No clear private burden is identified from the available clause analysis; implementing agencies may still take on administrative work.
Key Provisions
- Defines designates the first full week in May as Tardive Dyskinesia Awareness Week and promotes awareness of this medication side effect through encouraging early detection, intervention, and routine screening...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill defines designates the first full week in May as Tardive Dyskinesia Awareness Week and promotes awareness of this medication side effect through encouraging early detection, intervention, and routine screening.
Key Policy Areas
Healthcare, Trade
Primary Purpose
The bill defines designates the first full week in May as Tardive Dyskinesia Awareness Week and promotes awareness of this medication side effect through encouraging early detection, intervention, and routine screening.
Policy Domains
Senate Resolution
Identified Gains
- Mental health advocacy organizations and patient support groups
Sponsors
Legislative Progress
In CommitteeMr. Mullin (for himself and Mr. Padilla) submitted the following …
Referred to the Committee on the Judiciary. (text: CR S7851-7852)
Introduced in Senate
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Mental health advocacy organizations and patient support groups
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
Key Definitions
Terms defined in this bill
A movement disorder that can develop as a side effect of antipsychotic medications, requiring routine screening for early detection
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology